TCIM
EBS icon

TIAA CREF Investment Management’s Emergent Biosolutions EBS Stock Holding History

TIAA CREF Investment Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$5.49M Sell
108,720
-34,390
-24% -$2.03M ﹤0.01% 1380
2018
Q4 		$8.48M Sell
143,110
-65,043
-31% -$4.19M 0.01% 1032
2018
Q3 		$13.7M Sell
208,153
-1,183
-0.6% -$69K 0.01% 942
2018
Q2 		$10.6M Sell
209,336
-24,027
-10% -$1.25M 0.01% 1124
2018
Q1 		$12.3M Buy
233,363
+64,893
+39% +$3.23M 0.01% 998
2017
Q4 		$7.83M Buy
168,470
+81,125
+93% +$3.41M 0.01% 1295
2017
Q3 		$3.53M Sell
87,345
-2,754
-3% -$99.6K ﹤0.01% 1838
2017
Q2 		$3.06M Buy
90,099
+933
+1% +$28.8K ﹤0.01% 1910
2017
Q1 		$2.59M Sell
89,166
-5,220
-6% -$159K ﹤0.01% 1980
2016
Q4 		$3.1M Sell
94,386
-5,336
-5% -$160K ﹤0.01% 1932
2016
Q3 		$3.14M Sell
99,722
-1,445
-1% -$42K ﹤0.01% 1903
2016
Q2 		$2.85M Buy
101,167
+282
+0.3% +$11.1K ﹤0.01% 1916
2016
Q1 		$3.67M Sell
100,885
-5,866
-5% -$207K ﹤0.01% 1707
2015
Q4 		$4.27M Sell
106,751
-12,774
-11% -$445K ﹤0.01% 1665
2015
Q3 		$3.4M Sell
119,525
-5,542
-4% -$183K ﹤0.01% 1811
2015
Q2 		$4.12M Buy
125,067
+6,014
+5% +$186K ﹤0.01% 1817
2015
Q1 		$3.42M Sell
119,053
-702
-0.6% -$20.1K ﹤0.01% 1885
2014
Q4 		$3.26M Sell
119,755
-10,986
-8% -$262K ﹤0.01% 1929
2014
Q3 		$2.79M Sell
130,741
-31,382
-19% -$719K ﹤0.01% 2006
2014
Q2 		$3.64M Sell
162,123
-16,461
-9% -$383K ﹤0.01% 1907
2014
Q1 		$4.51M Sell
178,584
-2,980
-2% -$75.3K ﹤0.01% 1703
2013
Q4 		$4.17M Sell
181,564
-7,131
-4% -$149K ﹤0.01% 1771
2013
Q3 		$3.6M Sell
188,695
-12,306
-6% -$220K ﹤0.01% 1824
2013
Q2 		$2.9M Buy
+201,001
New +$2.91M ﹤0.01% 1918

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TIAA CREF Investment Management's EBS Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Emergent Biosolutions (EBS) stake by 24% in Q1 2019, selling an estimated $2.03M and leaving 108,720 shares worth $5.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1380.

TIAA CREF Investment Management first reported a position in EBS in Q2 2013 and has held it in 24 quarters since. The position peaked at $13.7M in Q3 2018. 272 funds tracked by Wall St. Rank hold EBS as of Q1 2019.

  • TIAA CREF Investment Management held 108,720 shares of Emergent Biosolutions worth $5.49M as of Q1 2019.
  • TIAA CREF Investment Management sold 34,390 Emergent Biosolutions shares in Q1 2019, an estimated $2.03M.
  • Emergent Biosolutions made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1380 holding.
  • TIAA CREF Investment Management first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Emergent Biosolutions position peaked at $13.7M in Q3 2018.
  • 272 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.